Primary Biliary Cholangitis Market Forecast 2025-2034: Evaluating Growth Factors, Segments, and Emerging Trends

What industry-specific factors are fueling the growth of the primary biliary cholangitis market?
The primary biliary cholangitis market is predicted to expand, attributable to the escalating rates of smoking. Inhaling and exhaling smoke from burnt tobacco or other substances is referred to as smoking, a widely recognized risk factor for liver diseases such as PBC. The rise in smoking prevalence may result in an increase in individuals seeking medical assistance for liver-related conditions. For instance, data from Statistics Canada, a government agency in Canada, in July 2023 shows a 2.2% increase in cigarette production compared to June 2023. Furthermore, a 2.6% surge in cigarette sales was observed in June, equating to 1.4 billion units, an increase from May. Consequently, the surge in smoking serves as a driving factor for the growth of the primary biliary cholangitis market. Primary Biliary Cholangitis Market Impetus: The Escalation in Liver Cancer Cases Propels Primary Biliary Cholangitis Market Growth

Get Your Primary Biliary Cholangitis Market Report Here:
https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

What Is the projected market size and growth rate for the primary biliary cholangitis market?
The market size for primary biliary cholangitis has seen swift expansion in previous years. We can expect this growth to continue, with projections indicating an increase from $0.98 billion in 2024 to $1.09 billion in 2025, boasting an impressive CAGR of 11.8%. The expansion seen in the historical timeline can be credited to heightened awareness of the disease, escalated worldwide healthcare spending, strategic partnerships within the healthcare industry, emphasis on patient advocacy, and government efforts to improve liver health.

The market size for primary biliary cholangitis is projected to experience significant growth in the upcoming years, swelling to a robust $1.6 billion by 2029. This corresponds to a compound annual growth rate (CAGR) of 9.9%. The anticipated market expansion in the forecast period is linked to the advancements in biomarker research, worldwide initiatives in rare disease management, the surge in clinical trial collaborations, emphasis on patient-oriented healthcare models, and the rising need for liver transplants. Key trends predicted for the forecast period involve the progression in biomarker research, increased focus on non-invasive diagnostic methods, research on immunomodulatory treatments, the incorporation of artificial intelligence (AI), incorporating patient's feedback in clinical trials, the use of telemedicine for patient care, focus on combined therapies, and novel treatments aimed at fibrosis.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

What new trends are reshaping the primary biliary cholangitis market and its opportunities?
Primary Biliary Cholangitis (PBC) market businesses are concentrating their efforts on creating unique and cutting-edge therapies, like orphan drugs that combine obeticholic acid (OCA) and bezafibrates for PBC treatment, to obtain market dominance. This combination of OCA and bezafibrate, coupled with an orphan drug designation, is viewed as an improved, more holistic method to manage PBC treatment and potentially enhance the life quality of those suffering from this unusual ailment. For instance, in May 2023, the FDA granted Intercept Pharmaceuticals, Inc., an American biopharmaceutical entity, an orphan drug designation for a potential PBC treatment that combines OCA and bezafibrate, a PPAR agonist. Additionally, obeticholic acid (sold under the brand name Ocaliva) has already gained approval for PBC treatment in the US.

What major market segments define the scope and growth of the primary biliary cholangitis market?
The primary biliary cholangitis market covered in this report is segmented -

1) By Treatment Type: Drugs, Liver Transplantation
2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses
3) By End-Users: Specialty Clinics, Homecare, Other End-Users

Subsegments:
1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies
2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13520

Which region dominates the primary biliary cholangitis market?
North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which key market leaders are driving the primary biliary cholangitis industry growth?
Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

What Is Covered In The Primary Biliary Cholangitis Global Market Report?

•Market Size Forecast: Examine the primary biliary cholangitis market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the primary biliary cholangitis market for a structured understanding.
•Key Players Overview: Analyze major players in the primary biliary cholangitis market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the primary biliary cholangitis market.
•Segment Contributions: Evaluate how different segments drive overall growth in the primary biliary cholangitis market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the primary biliary cholangitis market.
•Industry Challenges: Identify potential risks and obstacles affecting the primary biliary cholangitis market.
•Competitive Landscape: Review strategic developments in the primary biliary cholangitis market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.